HEADLINES:

Highlights from Medocity’s Presentation at DPharm 2021

News

Parsippany, NJ – October 5, 2021

Last week at the DPharm 2021 Conference, Medocity’s Global Head of Digital Clinical Trials, Amy Apostoleris, gave a spotlight presentation highlighting how a Composable Digital Platform can improve study outcomes, generate patient insights and support their disease journey. Here are a few key excerpts from her talk:

“We all know the era of decentralized clinical trials is here to stay, as the new normal. There are clearly many advantages to using a decentralized approach for clinical trials, especially during a pandemic. And while there are many benefits and even a critical need in some cases, now that we are experiencing decentralized trials more and more, we are noticing that there are also some downsides. One important aspect is that with reduced direct communication and connection between the patient, sites, and investigators, patients are expressing that they are feeling disconnected from the study, experiencing difficulties and burden, lacking guidance and engagement, some even not understanding the purpose of the study they are enrolled in. These experiences result in lower patient engagement and patient dissatisfaction which can potentially lead to non-compliance and reduced retention, resulting in three times more cost than planned.”

“So, how we can bring the patient to the center and engage and motivate them during a clinical trial and beyond to deliver better study outcomes and health outcomes? The Medocity Platform is rated highest in patient satisfaction, improved retention and better study outcomes among all digital health platforms. Our composable technologies have a long history of connecting oncology and CNS patients across the clinical ecosystem in a single solution, while also capturing patient data and insights to support the patient’s disease journey. We have also demonstrated through numerous peer reviewed studies that our platform has a 92% patient engagement and over 90% patient satisfaction among patients and providers, resulting in better study outcomes and improved management of patient health and well-being.”

View the entire presentation and learn more about how leveraging technology in decentralized trials can improve study outcomes for sponsors, patients, trial sites, and caregivers.

 

ABOUT MEDOCITY:
Medocity is a leading digital health solutions provider that supports decentralized clinical research and RWE generation through its unique, patient-focused end-to-end digital health enterprise platform serving pharmaceutical companies across clinical development and market commercialization. We collaborate with clinical development teams, CROs, sites and academic institutions from study concept to close, conducting decentralized clinical trials, including HEOR and RWE studies. Medocity engages patients throughout their disease journey to improve health outcomes; and enables the capture of continuous patient-centered data for trial and real-world clinical insights. Accessible in real time on any device, our technology seamlessly integrates with EMR data, claims data, lab data, EDC, CTMS and IRT systems, plus hundreds of connected sensors, sources and systems. Medocity’s unique AI/ML algorithm can match patients to rare disease clinical studies and also encourages inclusion and diversity. Our platform increases retention and compliance, accelerates study timelines, improves outcomes, and lowers healthcare costs. Any device. Any disease. Anywhere. Any time.

For more information, please visit www.medocity.com.

Medocity Media Contact:
Terence Maytin
‭(973) 671-5155
tmaytin@medocity.com

For Non-media Inquiries:
inquiry@medocity.com
(973) 679-8240

#     #     #